Literature DB >> 17592299

Staging systems for papillary thyroid carcinoma: a study of 2 tertiary referral centers.

Brian Hung-Hin Lang1, Sin-Ming Chow, Chung-Yau Lo, Stephen C K Law, King-Yin Lam.   

Abstract

OBJECTIVE: To find out the most applicable and consistent staging system for papillary thyroid carcinoma (PTC) available in the literature.
BACKGROUND: The commonly used staging systems for PTC have predicted cancer-specific survival (CSS) well. However, their applicability and generalizability have not yet been evaluated in different clinical settings.
METHODS: A MEDLINE search from 1965 to 2005 was carried out to identify different staging systems available in the literature and 9 systems were applicable to 1634 PTC patients within 2 tertiary-referral centers. The CSS of each staging system within individual centers were calculated using Kaplan-Meier method and the CSS of each tumor stage in one individual center was compared with that of the other by log-rank test. In addition, within each center, the predictability of each staging system relative to the others was ranked based on the proportion of variation explained (PVE) value.
RESULTS: Clinicopathologic features, treatment received, and tumor stages were significantly different between the 2 centers. There were also significant differences in CSS within at least one tumor stage between the 2 centers in 8 of the 9 staging systems. The TNM was a highly predictive and consistent staging system within the 2 centers. Although the absolute PVE values differed between the 2 centers, the relative ranking of the 9 staging systems within each center correlated significantly to each other (P < 0.05).
CONCLUSIONS: Despite referral, treatment, and data collection biases inherent within each center, the TNM system remained to be the most applicable and consistent staging system for PTC in 2 centers managing the same population group.

Entities:  

Mesh:

Year:  2007        PMID: 17592299      PMCID: PMC1899202          DOI: 10.1097/01.sla.0000262785.46403.9b

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  45 in total

Review 1.  Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer.

Authors:  E L Mazzaferri; R T Kloos
Journal:  J Clin Endocrinol Metab       Date:  2001-04       Impact factor: 5.958

2.  In-depth evaluation of the AJCC/UICC 1997 staging system of nasopharyngeal carcinoma: prognostic homogeneity and proposed refinements.

Authors:  Joseph S K Au; C K Law; W Foo; W H Lau
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-06-01       Impact factor: 7.038

3.  A novel classification system for patients with PTC: addition of the new variables of large (3 cm or greater) nodal metastases and reclassification during the follow-up period.

Authors:  Iwao Sugitani; Nobukatsu Kasai; Yoshihide Fujimoto; Akio Yanagisawa
Journal:  Surgery       Date:  2004-02       Impact factor: 3.982

4.  A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. Thyroid Cancer Cooperative Group.

Authors:  D P Byar; S B Green; P Dor; E D Williams; J Colon; H A van Gilse; M Mayer; R J Sylvester; M van Glabbeke
Journal:  Eur J Cancer       Date:  1979-08       Impact factor: 9.162

5.  An expanded view of risk-group definition in differentiated thyroid carcinoma.

Authors:  B Cady; R Rossi
Journal:  Surgery       Date:  1988-12       Impact factor: 3.982

6.  Natural history, treatment, and course of papillary thyroid carcinoma.

Authors:  L J DeGroot; E L Kaplan; M McCormick; F H Straus
Journal:  J Clin Endocrinol Metab       Date:  1990-08       Impact factor: 5.958

7.  Prognostic scoring systems in patients with follicular thyroid cancer: a comparison of different staging systems in predicting the patient outcome.

Authors:  A D'Avanzo; P Ituarte; P Treseler; E Kebebew; J Wu; M Wong; Q Y Duh; A E Siperstein; O H Clark
Journal:  Thyroid       Date:  2004-06       Impact factor: 6.568

8.  Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system.

Authors:  I D Hay; C S Grant; W F Taylor; W M McConahey
Journal:  Surgery       Date:  1987-12       Impact factor: 3.982

9.  Implications of prognostic factors and risk groups in the management of differentiated thyroid cancer.

Authors:  Ashok R Shaha
Journal:  Laryngoscope       Date:  2004-03       Impact factor: 3.325

10.  Application of staging systems for differentiated thyroid carcinoma in an endemic goiter region with iodine substitution.

Authors:  Christian Passler; Gerhard Prager; Christian Scheuba; Klaus Kaserer; Georg Zettinig; Bruno Niederle
Journal:  Ann Surg       Date:  2003-02       Impact factor: 12.969

View more
  18 in total

1.  Cancer: QTNM: a simplified TNM or just another staging system?

Authors:  Brian H H Lang; Chung-Yau Lo
Journal:  Nat Rev Endocrinol       Date:  2009-10       Impact factor: 43.330

2.  Validation of the QTNM staging system for cancer-specific survival in patients with differentiated thyroid cancer.

Authors:  Daniel Mankarios; Peter Baade; Pip Youl; Robin H Mortimer; Adedayo A Onitilo; Anthony Russell; Suhail A R Doi
Journal:  Endocrine       Date:  2013-10-31       Impact factor: 3.633

Review 3.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

4.  Outcome prediction with the revised American joint committee on cancer staging system and American thyroid association guidelines for thyroid cancer.

Authors:  Sunghwan Suh; Yun Hak Kim; Tae Sik Goh; Jin Lee; Dae Cheon Jeong; Sae-Ock Oh; Jong Chul Hong; Seong Jang Kim; In Joo Kim; Kyoungjune Pak
Journal:  Endocrine       Date:  2017-10-13       Impact factor: 3.633

Review 5.  New developments in the diagnosis and treatment of thyroid cancer.

Authors:  David F Schneider; Herbert Chen
Journal:  CA Cancer J Clin       Date:  2013-06-24       Impact factor: 508.702

6.  Validation and Comparison of Nomograms in Predicting Disease-Specific Survival for Papillary Thyroid Carcinoma.

Authors:  Brian Hung-Hin Lang; Carlos K H Wong
Journal:  World J Surg       Date:  2015-08       Impact factor: 3.352

7.  Does preoperative neutrophil lymphocyte ratio predict risk of recurrence and occult central nodal metastasis in papillary thyroid carcinoma?

Authors:  Brian Hung-Hin Lang; Cathy Po-Ching Ng; Kin Bun Au; Kai Pun Wong; Kandy K C Wong; Koon Yat Wan
Journal:  World J Surg       Date:  2014-10       Impact factor: 3.352

8.  Evaluating the morbidity and efficacy of reoperative surgery in the central compartment for persistent/recurrent papillary thyroid carcinoma.

Authors:  Brian Hung-Hin Lang; George C C Lee; Cathy P C Ng; Kai Pun Wong; Koon Yat Wan; Chung-Yau Lo
Journal:  World J Surg       Date:  2013-12       Impact factor: 3.352

Review 9.  The pros and cons of routine central compartment neck dissection for clinically nodal negative (cN0) papillary thyroid cancer.

Authors:  Ai Chen Chan; Brian Hung Hin Lang; Kai Pun Wong
Journal:  Gland Surg       Date:  2013-11

10.  Prognosis of differentiated thyroid cancer in relation to serum thyrotropin and thyroglobulin antibody status at time of diagnosis.

Authors:  Donald S A McLeod; David S Cooper; Paul W Ladenson; Kenneth B Ain; James D Brierley; Henry G Fein; Bryan R Haugen; Jacqueline Jonklaas; James Magner; Douglas S Ross; Monica C Skarulis; David L Steward; Harry R Maxon; Steven I Sherman
Journal:  Thyroid       Date:  2013-09-04       Impact factor: 6.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.